DEC1/STRA13 is a bHLH type transcriptional regulator involved with immune regulation, hypoxia response and carcinogenesis. We recently demonstrated that STRA13 interacts with STAT3 in the transcriptional activation of STAT-dependent promoters. Here, we pursue STRA13 involvement in the JAK/STAT pathway by studying its role in STAT1 expression. First, we showed that VHL deficiency or HIF-1 activation resulted in the repression of endogenous STAT1 mediated by STRA13. We then characterized the STAT1 proximal promoter to assess its response to STRA13 by transient coexpression in a luciferase reporter assay. Using sequential truncation and site-directed mutagenesis of the STAT1 promoter with STRA13 deletion constructs, we showed that the STRA13 C-terminal trans-activation domain, which is known to bind HDAC1, mostly determines the repressive activity. Involvement of HDAC activity in STAT1 regulation was validated by TSA inhibition and chromatin immunoprecipitation (ChIP) assay. Thus, we demonstrate that STRA13-mediated repression of STAT1 transcription utilizes an HDAC1-dependent mechanism. Furthermore, we show that targets of unphosphorylated STAT1, such as antigen presenting genes and CASP1, are also repressed by hypoxia possibly through the same STRA13-mediated mechanism. Thus, the newly discovered link between HIF-1 and STAT1 reveals a previously unknown role of STRA13 in hypoxia and carcinogenesis. Oncogene Shuai and Liu, 2003) . STAT1 and STAT3 are that two principal signal transducers in this pathway that serve disparate physiological roles through transcriptional activation of different targets (Qing and Stark, 2004) . In carcinogenesis, these proteins have opposite effects on cell growth and survival; while STAT3 is an oncogene (Bromberg et al., 1999), STAT1 possesses tumor suppressor properties (Kaplan et al., 1998; Bromberg and Darnell, 2000 ). STAT1's major functions, executed through the IFNg-induced Y701 phosphorylation, are inhibition of proliferation, activation of antimicrobial and antiviral responses, and induction of antitumor immune defense (Shuai et al., 1996; Kaplan et al., 1998; Stark et al., 1998) . Recent data suggest that unphosphorylated STAT1 may also play an important role in the regulation of constitutive expression of certain genes (Kumar et al., 1997; Chatterjee-Kishore et al., 2000; Meyer et al., 2002) .
Introduction
Hypoxic stress or VHL deficiency stabilizes HIF-1 and activates multiple VHL/HIF1 transcriptional targets (Maxwell et al., 1999; Maxwell, 2004) . The bHLH transcriptional factor STRA13/DEC1 is one of them (Ivanov et al., 1998 (Ivanov et al., , 2001 , with an as yet unclear role in the hypoxic response and poorly investigated downstream targets. STRA13 is expressed in differentiating embryonic and adult tissues (Boudjelal et al., 1997; Shen et al., 1997) , responds to a broad range of growth stimuli (Shen et al., 2001; Zawel et al., 2002) , and serves as a key regulator of lymphoid cell development and activation (Sun et al., 2001; Seimiya et al., 2004) . Transcriptional repression activity of STRA13 can be established through direct DNA binding to the E-box (St-Pierre et al., 2002; Zawel et al., 2002; Azmi et al., 2003) via its basic region, or through indirect involvement in transcriptional modulation via interaction with multiple transcription factors, such as USF (Dhar and Taneja, 2001) , TBP and TFIIB (Boudjelal et al., 1997) , MyoD (Azmi et al., 2003) , and MSP58 (Ivanova et al., 2005) , or with the HDAC complex components (Sun and Taneja, 2000) . Recently, our data on the interaction of STRA13 with STAT3 (Ivanova et al., 2004) implicated STRA13 in the JAK/STAT signal transduction pathway that plays a central role in regulation of the immune system (Bach et al., 1997; Shuai and Liu, 2003) . STAT1 and STAT3 are that two principal signal transducers in this pathway that serve disparate physiological roles through transcriptional activation of different targets (Qing and Stark, 2004) . In carcinogenesis, these proteins have opposite effects on cell growth and survival; while STAT3 is an oncogene (Bromberg et al., 1999) , STAT1 possesses tumor suppressor properties (Kaplan et al., 1998; Bromberg and Darnell, 2000 ). STAT1's major functions, executed through the IFNg-induced Y701 phosphorylation, are inhibition of proliferation, activation of antimicrobial and antiviral responses, and induction of antitumor immune defense (Shuai et al., 1996; Kaplan et al., 1998; Stark et al., 1998) . Recent data suggest that unphosphorylated STAT1 may also play an important role in the regulation of constitutive expression of certain genes (Kumar et al., 1997; Chatterjee-Kishore et al., 2000; Meyer et al., 2002) .
In this study, we identify STAT1 as a transcriptional target of STRA13, investigate the molecular mechanisms of STRA13 activity on the STAT1 promoter, and assess the downstream effects of this activity.
Results

Introduction of VHL in clear cell carcinoma cells stimulates STAT1 expression
Our previous study revealed functional interaction between a VHL/HIF-1 target STRA13 and STAT3 (Ivanova et al., 2004) . To find out if STRA13 can be associated with other constituents of the JAK/STAT pathway, we took advantage of cell lines with different VHL status. The original clear cell carcinoma cell lines UM-RC-6 and 786-0 contain frameshift mutations in the remaining VHL allele that make aberrant proteins incapable of targeting and degrading HIF-a, leading to hypoxia-like conditions. To create a tool for identification of hypoxia-associated genes, these original cell lines were transfected with wild-type (wt) or mutant VHL transgenes (Ivanov et al., 1998) . Mammalian cells produce two differentially spliced isoforms of STAT1 mRNA that correspond to two distinct proteins, a(p91) and b(p84) (Schindler et al., 1992) . 786-0 cells constitutively transfected with the wt VHL gene showed a B2.5-fold upregulation in endogenous levels of both STAT1 mRNA isoforms when compared with the original VHL-deficient cell line or mutant VHL-transfected cells (Figure 1a) . The stimulating effect of VHL on STAT1 expression was reproduced on the protein level in both 786-0 and UM-RC-6 (Figure 1b) . No variation was observed between 786-0 and UM-RC-6 in the levels of STAT1 or STRA13 in spite of the fact that these cell lines produce different HIF-a subunits (UM-RC-6 expresses HIF-1a, while 786-0 -HIF-2a (Martin-Puig et al., 2004) ). Our analysis of the VHL effect on STAT3 (Figure 1b ) and other STATs' expression (data not shown) demonstrated that only STAT1 expression is modulated by pVHL.
VHL has no effect on STAT1 phosphorylation Phosphorylation of STAT1 is critical for the IFN-a, -b, and -g pathways (Darnell, 1998) . To provide more insight into the VHL effect on STAT1, we next sought to determine if STAT1 phosphorylation is VHL-dependent.
786-0 cells were stimulated with IFN-g, and endogenous STAT1 protein levels assessed in treated and nontreated cells by Western blot. Both VHL-deficient and VHLpositive 786-0 cells responded to the IFN-g treatment by a dramatic transient upregulation of both Y701-phosphorylated STAT1 species, but produced no rapid change in the total pool of STAT1 proteins (compare 15 min of IFN-g treatment with point 0 on Figure 2 ). While prolonged IFN-g treatment caused upregulation of both STRA13 and STAT1, stimulation was more pronounced in the STRA13 case (compare points 0 and 18 h). VHL-positive 786-0 cells showed an increase in the basal (unphosporylated) STAT1 proteins as compared to VHL-deficient cells (compare first two lanes, top row, on Figure 2 ). VHL status, however, had no effect on Y701 phosphorylation, since rows 2 and 3 from top showed the same amount of protein in VHL-positive and negative cells. Interestingly, while the level of Y701-phosphorylation in both cases significantly declined after 18 h, total STAT1 protein amount was markedly upregulated suggesting a long-lasting stimulating effect of IFN-g on STAT1 transcription. Full activation of STAT1a by IFN-g requires phosphorylation on S727 (Wen et al., 1995) . 786-0 cells showed constitutive S727 phosphorylation that was not affected by IFN-g stimulation or VHL status (data not shown). These results combined with our data shown in Figure 1 implied that VHL stimulated constitutive production of STAT1 mRNA and unphosphorylated protein, but had no impact on STAT1 phosphorylation.
Inverse correlation between STAT1 and STRA13 expression and regulation of STAT1 transcription by HIF-1a and STRA13 The fact that pVHL stimulates STAT1 expression prompted us to investigate the molecular mechanism of this effect. We previously demonstrated that pVHL downregulates STRA13 expression on the mRNA level (Ivanova et al., 2001) . In this study, using recently developed antibodies against endogenous STRA13, we observed a correlation between upregulation of STAT1 and downregulation of the STRA13 protein in VHLpositive renal clear carcinoma cells, as compared to VHL-deficient cells (Figures 1b and 2 ). In the course of IFN-g treatment, however, this negative correlation was not as pronounced, probably due to the fact that these gene products are tightly regulated by multiple factors. To examine if such correlation is seen on the mRNA level, four different cell lines were exposed to hypoxia and 0.5 mM NiSO 4 , used as a hypoxia mimetic. Hypoxic conditions produced elevated levels of STRA13 and decreased levels of STAT1 transcripts. Overall, the correlation coefficient between STRA13 and STAT1 band intensities in Figure 3a was -0.8. Normal (1HAEo(À) and MRC-5) and cancer (U-87, U-251, LN-229) cell lines showed similar response suggesting that this effect is consistent and not cancer-specific. The observed hypoxic repression of STAT1 inversely associated with STRA13 expression prompted us to investigate whether STAT1 is a HIF-1 target regulated via STRA13. To test if STRA13 effect is HIF-1 dependent, we used MEFs with targeted HIF-1a (Salnikow et al., 2004a) and showed that HIF-1-deficient cells were not able to repress STAT1 at hypoxic conditions ( Figure 3b ). This experiment unequivocally proved that STAT1 is a HIF-1 target. Finally, we used HaCat keratinocytes with inactivated STRA13 gene (Zawel et al., 2002) to further corroborate STRA13 repressive activity on endogenous STAT1 (Figure 3c ). Characterization of the STAT1 proximal promoter and its STRA13-dependent activity To test if STRA13 is capable of STAT1 suppression on the transcriptional level, we used phSTAT1 reporter constructs described earlier (Bai and Merchant, 2003) to identify and characterize the STAT1 proximal promoter. Transcriptional activity of these constructs in 293T cells, with or without forced STRA13 expression, was evaluated using a luciferase reporter system. Out of three constructs, only phSTAT1-1856 showed a substantial transcriptional activity and appeared to be STRA13-dependent, producing a Bfourfold repression when co-transfected with STRA13 expression construct (Figure 4a and b). This observation prompted us to focus on the 1035 bp DNA fragment 5 0 -adjacent to the STAT1 transcription initiation site. Using in silico analysis, we identified in this area a potential CCAATand ISRE-containing promoter (pos. 90226-90852, reverse, GenBank accession # AC067945). The ISRE sequence (IFN-stimulated response element with consensus AGTTTCNNTTTCNY) is a common element of IFN-responsive promoters that can be bound and transactivated by the IFN-inducible STAT1/STAT2/IRF-9 complex, as well as other IRFs (Stark et al., 1998) . In our attempt to further delineate the STRA13-dependent region, we created two deletion mutants of the 1035 bp fragment, phSTAT1b and phSTAT1c (Figure 4a and c).
As promoter activity and STRA13-dependent repression on both of them were very similar to that of the phSTAT1-1856 construct (data not shown), our further studies were performed on phSTAT1c (365 bp, pos. 90287-90651 on AC067945). This DNA sequence is in transcriptional response to hypoxic conditions. Responsiveness of four cell lines to hypoxia and nickel was tested by RT-PCR on STRA13 and STAT1 transcripts. CA9 was used as a positive control for hypoxia (Ivanov et al., 1998) . RNA input was 50 ng per RT-PCR reaction. The ribosomal protein gene RPLP0 used as a loading control. Cycle numbers were optimized to avoid overproduction and are shown for STRA13 and CA9 on the right. Cycle number for STAT1 was 32 for lanes 1-9 and 26 for lanes 10-12, for CA9 -32 for lanes 1-3, 20 for lanes 4-9, and 26 for lanes 10-12. Cells were incubated with 0.5 mM NiSO 4 or in hypoxia for 20 h. 
STRA13 represses the STAT1 promoter independently of E-boxes, c-Myb, or ISRE motifs
As truncation of phSTAT1c to its 3 0 -half (construct phSTAT1e, marked with arrow in Figure 4c ) caused a significant loss of basal transcriptional activity (Figure 5a ), we considered phSTAT1c the STAT1 minimal promoter. Notably, phSTAT1e transcriptional activity remained to be STRA13-dependent (Figures 4a  and 5a ). Thus, serial truncation of the STAT1 promoter in the 5 0 -3 0 direction from 1035 to 180 bp failed to confine STRA13 repressive activity to any specific segment of DNA.
To test if STRA13 repressive activity can be linked to any protein-binding motifs identified in the minimal 0 -truncated derivative phSTAT1e. The transcription initiation site is shown as defined by (Wong et al., 2002) . The 3 0 -proximal sequence conserved between mouse and human is shown in bold.
promoter sequence, we used site-directed mutagenesis ( Figure 4c ). Mutations introduced in E1 and c-Myb produced a limited effect on basal transcription and no effect on the STRA13 repressive activity (Figure 5a ). Mutation of the ISRE element caused a dramatic reduction (approximately fivefold) of basal phSTAT1c transcriptional activity implicating this STAT-binding motif in the regulation of promoter activity. However, the mutated ISRE did not change the STRA13 repressive capacity (Bfourfold repression remained), ruling out direct interaction between STRA13 and ISRE. Finally, introduction of mutations in the remaining E2-box (pos. 194-199 in Figure 4c ) also did not result in any change in the STRA13 repressive effect (data not shown). STRA13/BHLHB2 repressive activity is known to utilize either binding to the E-box or interaction with other transcription factors in different signaling contexts. In our study, two independent lines of evidence, serial truncation of the promoter and mutational analysis of putative STRA13-binding sites, suggested involvement of STRA13 in the interaction with basal transcriptional machinery rather than direct binding of the repressor to promoter DNA.
The C-terminal transactivation domain is critically important for the STRA13 repressive activity For mapping STRA13 domains involved in transcriptional repression of the STAT1 promoter, we used the STRA13 deletion constructs described earlier (Ivanova et al., 2004) . Co-expression of construct 68-412 (lacking the basic domain), 123-412 (devoid of both the basic and HLH domains), or 1-299 (devoid of the C-terminal transactivation domain) with phSTAT1-1856 Lucreporter showed that elimination of the C-terminus virtually abrogated STRA13 suppression activity. Deletion of the basic or bHLH domains reduced this activity only partially (Btwofold) (Figure 5b ). These results highlight the critical importance of the STRA13 C-terminus for the transcriptional repression. As the STRA13 C-terminal region was previously associated with protein-protein interaction (Sun and Taneja, 2000; Ivanova et al., 2004 Ivanova et al., , 2005 , the obtained data suggested a cooperation between STRA13 and other transcriptional regulator(s) on the STAT1 promoter.
Involvement of HDAC activity in the regulation of the STAT1 minimal promoter As our experiments showed the critical importance of the STRA13 C-terminal protein-binding domain for the STAT1 promoter repression and a limited involvement of the STRA13 DNA-binding domain, we searched for STRA13-interacting proteins that could contribute to its repressive activity. STRA13 was previously associated with HDAC1, which interacts with the STRA13 C-terminal domain (Sun and Taneja, 2000) . Also, induction of interferon-stimulated genes requires histone deacetylase activity (Sun and Taneja, 2000; Chang et al., 2004) . These observations prompted us to examine the effect of trichostatin A (TSA), a specific histone deacetylase inhibitor, on the STAT1 minimal promoter in a co-transfection assay. The addition of TSA downregulated the minimal STAT1 promoter B2.5-to threefold and abrogated the STRA13 repressive effect as assessed by luciferase activity (Figure 6 ). A similar effect was obtained on the full-length promoter phSTAT1-1856 (data not shown). These observations suggest involvement of HDAC activity in both STAT1 basal transcription regulation and STRA13-dependent repression.
Recruitment of HDAC1 to the STAT1 promoter is suppressed by hypoxic conditions To further pursue HDAC involvement in the hypoxic regulation of STAT1, we explored HDAC1 binding to the STAT1 promoter using chromatin immunoprecipitation assay. As shown in Figure 7 , treatment of 1HAEo(À) cells with 0.5 mM NiSO 4 significantly reduced binding of HDAC1 to the STAT1 promoter supporting HDAC1 involvement in STAT1 hypoxic repression. The observed effect could not be explained simply by HDAC1 expression downregulation at hypoxic conditions, since incubation with Ni produced no change in HDAC1 level but dramatically upregulated STRA13 expression (Western blot data not shown). The incubation with Ni had no visible effect on the amount of acetylated H3, p300, and RNA pol II, indicating that the HDAC1 substrate and cooperating transcription factors remain to be identified.
Repression of LMP2 and other ISRE-containing genes by VHL deficiency or hypoxia After we demonstrated involvement of STRA13 and HDAC in the regulation of the STAT1 promoter, our next goal was to study if other IFN-stimulated promoters can be repressed by hypoxic conditions. One well-known IFN-g/STAT1 target is the LMP2 gene, which encodes a subunit of the 20S proteasome, implicated in antigen presentation via MHC class I molecules (Chatterjee- Kishore et al., 2000) . We studied the effect of VHL on LMP2 expression in 786-0 cells. Both STAT1 and LMP2 showed a VHL-dependent modulation of constitutive expression in nontreated cells (Figure 8a) and were approximately twofold upregulated. In contrast, pVHL downregulated STRA13 B1.4-fold in agreement with the hypothesis that LMP2 is a VHL target regulated via STRA13. We then tested if similar effects could be observed on a hypoxic background. Indeed, incubation of minimally transformed human lung epithelial 1HAEo(À) cells with 0.5 mM NiSO 4 caused a B2-4-fold downregulation of STAT1 and virtually abrogated constitutive LMP2 expression, while the STRA13 level was B2.4-fold increased (Figure 8b ). These data further substantiate the physiological importance of hypoxic signaling to STAT1 and LMP2. Since HIF-1 stimulates both STRA13 (Miyazaki et al., 2002) and represses STAT1 (Figure 3c ), we then sought to verify HIF-1 involvement in LMP2 repression. We took advantage of the fact that HIF-1a is unstable in the presence of ascorbate, a cofactor of prolyl hydroxylases (Salnikow et al., 2004a) . Addition of 50 mM ascorbate to NiSO 4 -containing media partially restored expression of both the LMP2 and STAT1 genes ( Figure 8c ). Thus, our experiments confirm that hypoxia and VHL are both capable of LMP2 transcriptional modulation, and that this effect is most likely mediated by STRA13 and STAT1 in a HIF1-dependent manner.
Seeking other IFN-associated genes that can be repressed by hypoxia, we applied RT-PCR to total RNA samples isolated from VHL-positive or negative cells with or without IFN-g stimulation. As a result, we expanded the list of VHL targets with MHC class I associated genes, such as HLA-A, -B, and -C, TAP2, and LMP7 ( Figure 8d ). As in the STAT1 case, promoters of HLA class I genes are controlled via the conserved ISRE motif (van den Elsen et al., 2004) . Transcriptional activation from ISRE requires cooperation of STAT1, STAT2 and IRF-9 (Horvath, 2000) . Remarkably, we showed that 786-0 cells expressed IRF-9 in a VHL-dependent manner providing further support for the involvement of ISRE in hypoxiaassociated regulation of constitutively expressed STAT1 targets. Expression of IRFs 3 and 4 in 786-0 was not detectable, while IRF-1 was expressed but showed no association with VHL ( Figure 8e and data not shown).
The MHC class II genes are another set of immunityassociated genes induced by IFN-g and tightly regulated at the transcriptional level (Glimcher and Kara, 1992) . VHL-deficient 786-0 cells showed a low-level constitutive expression of HLA-DP and HLA-DMA, while HLA-DR expression was not detectable (Figure 8e ). Introduction of wt VHL stimulated basal expression of Figure 7 Incubation with Ni prevents the recruitment of HDAC1 to the STAT1 promoter. 1HAEo(À) cells were incubated with or without 0.5 mM NiSO 4 for 20 h. Chromatin fragments were immunoprecipitated with antibodies against acetylated histone 3, HDAC1, p300, RNA polymerase II, or mock antibodies and the STAT1 promoter region (À152 to À402) was amplified by PCR. We were unable to detect the STAT1 promoter when mock IgG was used. 2002)). Our assessment of expression of these apoptosisassociated genes in 786-0 cells showed that CASP1, but not CASP2 or 3, was considerably upregulated by the WT VHL gene (Figure 8f ). The hypothesis that this effect is also mediated via STRA13 was tested on STRA13-deficient HaCat keratinocytes subjected to hypoxia (Figure 8g ). This experiment showed that while normal HaCat cells are capable of CASP1 hypoxic repression (lanes 1 and 3) , STRA13-deficient cells lost such a capacity (lanes 2 and 4) . Thus, STRA13 may serve as a CASP1 repressor via downregulation of STAT1 transcription.
Discussion
While tumor suppressor properties of STAT1 were recognized a few years ago, they have been associated mostly with IFN-g and phosphosylated STAT1 (Kaplan et al., 1998; Bromberg and Darnell, 2000) . However, the recent finding that methylation of the STAT1 promoter is critical for squamous carcinoma progression (Xi et al., 2006) combined with the data on transcriptional activity of unphosphorylated STAT1 protein (Kumar et al., 1997; Chatterjee-Kishore et al., 2000; Meyer et al., 2002) underscore the importance of transcription in the regulation of STAT1 activity. Our previous studies on the role of hypoxia-inducible STRA13 suggested a connection between STRA13 and the JAK/STAT pathway. Here, for the first time, we demonstrate that hypoxia has a negative impact on STAT1 transcription, and that this effect is mediated by STRA13, which serves as a STAT1 repressor.
Pursuing the molecular mechanisms of the STRA13 repressive effect, we isolated and characterized the STAT1 ISRE-type proximal promoter and implicated histone deacetylase activity in its stimulation. These findings are consistent with the recent reports on the requirement of HDAC for stimulation of IFN-g inducible targets (Nusinzon and Horvath, 2003; Chang et al., 2004; Sakamoto et al., 2004) and with the data on the functional interaction of STRA13 with HDAC1 (Sun and Taneja, 2000) . Suppression of HDAC1 binding to the STAT1 promoter by NiSO 4 (Figure 7) , a well-established chemical inducer of hypoxia-responsive genes such as STRA13 (Figure 3a) , suggests that sequestering HDAC1 by STRA13 from the STAT1 promoter is the most plausible mechanism for STAT1 hypoxic repression.
While deficiency of phosphorylated STAT1 is known to cause suppression of both the adaptive and innate immune systems (Kaplan et al., 1998) , the biological significance of transcriptional modulation of STAT1 remained poorly investigated. In our study, we succeeded in linking VHL inactivation with the repression of STAT1-dependent antigen-presenting genes, such as MHC classes I and II genes, and CASP1. We show that events downstream from transcriptionally modulated STAT1 are different from the ''classic'' IFN-g-responsive pathway because CIITA, the master coordinator of IFN-g-dependent signaling (van den Elsen et al., 2004), is not involved in the regulation of constitutively expressed STAT1 targets. Instead, the hypoxic mechanism may recruit other STAT1-associated transcriptional regulators, such as IRF9.
It was previously reported that renal cell carcinomas and other tumors downregulate expression of the MHC I and II HLA genes (Gastl et al., 1996; Osborne et al., 1997; Atkins et al., 2004; Satoh et al., 2004; Zagzag et al., 2005) . As it is commonly believed that abnormalities in antigen presentation may help tumors evade the full-scale immune response (Seliger et al., 2000) , the molecular mechanisms of such deficiencies may provide a clue to novel therapeutic approaches. Studies on the HLA-DRA promoter in breast carcinoma cells showed that Rb protein introduction stimulated basal HLA-DR expression in a CIITA-independent manner (Osborne et al., 1997) . It is tempting to hypothesize, therefore, that the newly characterized link between VHL/HIF and the regulation of HLA genes is a yet another example of such a mechanism that predisposes tumors to a low-level constitutive immunogenicity and obstructs immune reaction. The connection found between hypoxia and CASP1 downregulation is also intriguing. To our knowledge, CASP1 expression has never been reported to be hypoxia-dependent. The new link identified between HIF-1/STRA13 and CASP1 may provide a better insight into the regulation of apoptosis and inflammation in hypoxic tumors.
In conclusion, our results can be summarized in a scheme where STRA13 provides a previously unknown link between hypoxia, STAT1, and targets of unphosphorylated STAT1 (Figure 9 ). It remains to be determined, which of the vital STAT1 functions, growth-suppressive, proapoptotic or proinflammatory, can be affected through the VHL/HIF1 pathway. The events triggered by hypoxia downstream unphosphorylated STAT1 require more research since ISRE-containing promoters of IFN-inducible genes are known to be regulated via transcriptional cooperation between STATs, IRFs, CBP/p300, HDACs, NFkB, and other factors (Shuai et al., 1996) . The STRA13 role in these multiple interactions and different physiological contexts must be defined.
Besides hypoxia, STRA13 can be induced by a variety of other stimuli, such as TGF-b (Zawel et al., 2002) , cytokines (Ivanova et al., 2004) , retinoic acid (Boudjelal et al., 1997), insulin (Yamada et al., 2003) and light (Honma et al., 2002) . It appears that in many of these seemingly disparate physiological contexts, STRA13 0 s main function is relaying suppressive environmental signals to STAT1 and other ISRE-containing genes. Association of STRA13 activity with various stress factors, such as hypoxia (Wykoff et al., 2000; Ivanova et al., 2001; Miyazaki et al., 2002) , light (Honma et al., 2002) and serum deprivation (Sun and Taneja, 2000; Li et al., 2002) fits well into the emerging role of the JAK/ STAT pathway in mediating the diverse cellular responses to stress (Dudley et al., 2004) . In our previous study, we showed that STRA13 may cooperate with STAT3 in transcriptional regulation via the GAS, ISRE and STAT3 cis-elements (Ivanova et al., 2004) . Our present data linking STRA13 with the negative regulation of STAT1 and its targets shed more light on STRA13's newly discovered role in balancing the transcriptional activities of STAT1 and STAT3.
Materials and methods
Cell lines, VHL and STRA13 expression constructs, and STAT1 reporter assay Renal clear cell carcinoma cell lines 786-0 and UM-RC-6 were incubated to late confluent stage to ensure maximum effect of VHL on its transcriptional targets. Mutant (mut 2) or transgenic wild-type VHL (wtVHL) constructs used in these study were described earlier (Ivanov et al., 1998) . Human 293T embryonic kidney cell line was purchased from ATCC; LN-229 (glioma) and U-251 (astrocytoma) were kindly provided by Dr D Zagzag, and MRC-5 cells (normal untransformed human fetal lung fibroblasts) were purchased from Coriell Cell Repositories, Camden, NJ, USA. Human lung minimally transformed epithelial 1HAEo(À) cells were described elsewhere (Salnikow et al., 2004b) . MEF þ / þ and MEF HIF-1À/À were obtained from Dr R Johnson (University of California San Diego, CA, USA) and were described previously (Salnikow et al., 2000) . HaCat cells with targeted STRA13 gene, described previously (Zawel et al., 2002) , were kindly provided by Dr B Vogelstein (Howard Hughes Medical Institute and The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions). STRA13 deletion constructs were produced and verified earlier (Ivanova et al., 2004) . STAT1 reporter constructs phSTAT1-1856, 1-888 and 1-300 were described in Bai and Merchant (2003) . Additional constructs phSTAT1b, phSTAT1c and phSTAT1e were generated by PCR on the phSTAT1-1856 template and then cloned into the KpnI/ HindIII site of the pGL3-Basic vector.
Northern and Western blot analyses
Cell cultures were grown in DMEM or EMEM media. To produce hypoxic conditions cells were incubated in a chamber in the atmosphere containing 0.5% O 2 , 5% CO 2 , and 94.5% N 2 at 371C for 20 h. To mimic hypoxic conditions, cells were incubated with 0.5 mM NiSO 4 or 0.2 mM desferoxamine for 20 h. RNA samples were extracted with RNeasy Mini total RNA (Qiagen, Valencia, CA, USA) or FastTrack polyA RNA (Invitrogen, Carlsbad, CA, USA) kits. For Western blot, cells were lysed in RIPA buffer and proteins fractionated as described earlier (Ivanova et al., 2004) . STRA13 antibodies against the endogenous protein were ordered from Washington Biotechnology (Washington, DC) and validated in our previous study (Ivanova et al., 2005) . STAT1 and STAT3 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The pY701 STAT1 and pS727 STAT1 antibodies were produced by Cell Signaling Technology (Beverly, MT, USA). For quantification of Northern blot data, we used the Packard Cyclone Storage Phosphor System (PerkinElmer, Shelton, CT, USA).
RT-PCR analysis: optimization, loading control, and quantitative assessment RT-PCR reactions were standardized using the GeneFisher Primer Design web site (http://bibiserv.techfak.unibielefeld.de), SuperScriptt One Step RT-PCR kit (Invitrogen, Carlsbad, CA, USA), and universal RT-PCR protocol: 501C-30 min, 941C-2 min, 25-30 cycles of (941C-15 s, 561C-30 s, 701C-60 s), 701C-5 min. cDNA sequences for genes of interest were extracted from the Source web site (http://source. stanford.edu/cgi-bin/source/source), and primers were designed to produce B1 kb PCR products as follows:
Human 0 . Reliability and accuracy of RT-PCRbased comparison was tested by measurements in triplicate experiments. As a loading control, we used the gene encoding ribosomal protein RPLP0 recommended by (http:// pathmicro.med.sc.edu/pcr/realtime-home.htm), AKTB, or USP11. After separation of RT-PCR products in a conventional agarose gel, intensities of ethidium bromide stained DNA bands were measured using Kodak 1D 3.6.3 Network Software. The correlation coefficient was calculated using the UCLA Department of Statistics website (http://calculators. stat.ucla.edu/correlation.php).
Luc-reporter assay
Thirty thousand 293T cells per well were plated into 96-well plates in 100 ml media. On the next day, cells were transfected with 75 ng/well of the STAT1 promoter constructs and 75 ng/ well of the STRA13 expression plasmid, or empty vector and 50 ng/well of pCMV-Renilla luciferase (RL-CMV), using the transfection reagent effecten (Qiagen, Valencia, CA, USA). After overnight incubation, plasmid expression was allowed for 24-36 h. The reporter expression was detected using the Dual-Glo luciferase system (Promega, Madison, WI, USA) and the MicroLumat LB 96V Luminometer (Bad Wildbad, Germany). The data are presented as mean values 7s.d. of normalized relative luciferase units (RLU), which represent the ratio of luminescence produced by the STAT1 promoter-Luc plasmid to the luminescence of the RL-CMV reporter in the same well. Each condition has been tested in quadruplicate in at least three independent experiments.
Stimulation of 786-0 cells with INF-g
Cells grown in DMEM media supplemented with bovine fetal serum were stimulated with INF-g (Upstate Biotechnology, Waltham, MA, USA) at the final cytokine concentration 1000 m/ml.
STAT1 promoter analysis
For promoter prediction and analysis, we used Genomatix (http://www.genomatix.de/) and Motif (http://motif.genome.jp) servers. Introduction of mutations into the putative protein-binding motifs, identified in the promoter sequence, was made with Stratagene (La Jolla, CA, USA) Quick Change Site-Directed Mutagenesis kit according to the manufacturer's protocol.
Chromatin immunoprecipitation assay
For immunoprecipitation studies on the STAT1 promoter, we used Active Motif ChIP-IT kit (Carlsbad, CA, USA) and RNA polymerase II antibodies according to the manufacturer's instructions. Antibodies against acetyl-H3, HDAC1 and p300 were purchased from Upstate Cell Signaling Solutions (Lake Placid, NY, USA). PCR primers for the STAT1 promoter were 5 0 -CCCTGGGTTTAGCAACAC-3 0 (pos. 90721-90704 on AC067945) and 5 0 -GCGCTGGGG TATTTCC-3 0 (pos. 90449-90471 on AC067945).
Abbreviations
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